Evidence of circulating NET biomarkers in serum of patients with TRALI
| Sample no. . | GAT . | DNA, ng/mL . | MPO, mU/mL . | Nucleosomes (OD 405-490) . |
|---|---|---|---|---|
| Specificity | ||||
| TRALI patient 1 | ± | 479 | 360.7 | 0.11 |
| TRALI patient 2 | ± | 473 | 270.8 | 0.40 |
| TRALI patient 3 | ± | 270 | 112.4 | 0.20 |
| TRALI patient 4 | ± | 523 | 466.5 | 0.50 |
| TRALI patient 5 | ± | 522 | 55.5 | 0.11 |
| Group median | 479 | 270.8 | 0.20 | |
| Normal control 1 | − | 266 | 39.7 | 0 |
| Normal control 2 | − | 294 | 79.6 | 0.01 |
| Normal control 3 | − | 250 | 45.9 | 0.06 |
| Normal control 4 | − | 221 | 243 | 0.10 |
| Normal control 5 | − | 241 | 87.4 | 0.07 |
| Normal control 6 | − | 235 | 138.9 | 0.05 |
| Group median | 245 | 83.5 | 0.06 | |
| P | .0087 | .1255 | .0043 |
| Sample no. . | GAT . | DNA, ng/mL . | MPO, mU/mL . | Nucleosomes (OD 405-490) . |
|---|---|---|---|---|
| Specificity | ||||
| TRALI patient 1 | ± | 479 | 360.7 | 0.11 |
| TRALI patient 2 | ± | 473 | 270.8 | 0.40 |
| TRALI patient 3 | ± | 270 | 112.4 | 0.20 |
| TRALI patient 4 | ± | 523 | 466.5 | 0.50 |
| TRALI patient 5 | ± | 522 | 55.5 | 0.11 |
| Group median | 479 | 270.8 | 0.20 | |
| Normal control 1 | − | 266 | 39.7 | 0 |
| Normal control 2 | − | 294 | 79.6 | 0.01 |
| Normal control 3 | − | 250 | 45.9 | 0.06 |
| Normal control 4 | − | 221 | 243 | 0.10 |
| Normal control 5 | − | 241 | 87.4 | 0.07 |
| Normal control 6 | − | 235 | 138.9 | 0.05 |
| Group median | 245 | 83.5 | 0.06 | |
| P | .0087 | .1255 | .0043 |
The degree of agglutination was graded from − (negative), ± (weak), or + (positive). DNA, MPO, and nucleosome levels are compared in serum from patients with TRALI with control serum (P = .0087, .1255, and .0043, respectively). Analysis was performed blinded to sample origin. All the TRALI patients' samples were higher than all control samples for at least 1 biomarker.